An experimental, proprietary cannabinoid-based drug in development for diabetic neuropathy outperformed pregabalin in a clinical trial, achieving significant reduction in pain severity, new topline results released by Zelira Therapeutics suggest.
"Through this rigorously designed study, we have demonstrated that ZLT-L-007 is a safe, effective, and well-tolerated alternative for patients who would typically seek a Lyrica-level of pain relief," he added. For the pregabalin only group, there was a reduction in symptom severity at all follow-up points, ranging from 20% to 35% , the company said.
For the pregabalin plus ZLT-L-007 group, there was a moderate 20% reduction in symptom severity at 30 days, but a larger reduction at 60 and 90 days , which indicates substantially greater improvement in symptom severity than with pregabalin alone, the company said.